BNP Paribas Financial Markets Has $1.80 Million Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

BNP Paribas Financial Markets lessened its position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 49.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 59,710 shares of the biopharmaceutical company's stock after selling 58,275 shares during the period. BNP Paribas Financial Markets' holdings in TG Therapeutics were worth $1,797,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of TGTX. Quadrant Capital Group LLC lifted its stake in TG Therapeutics by 137.1% in the 4th quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company's stock valued at $51,000 after purchasing an additional 975 shares during the last quarter. Blue Trust Inc. raised its stake in TG Therapeutics by 24.5% in the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock valued at $57,000 after buying an additional 371 shares during the period. Smartleaf Asset Management LLC lifted its position in shares of TG Therapeutics by 512.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company's stock valued at $60,000 after buying an additional 1,594 shares during the last quarter. Jones Financial Companies Lllp boosted its stake in shares of TG Therapeutics by 460.7% during the 4th quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company's stock worth $64,000 after acquiring an additional 1,737 shares during the period. Finally, Synergy Asset Management LLC acquired a new position in shares of TG Therapeutics during the 4th quarter worth approximately $75,000. Institutional investors own 58.58% of the company's stock.

TG Therapeutics Stock Performance

TGTX stock traded up $0.29 during trading hours on Thursday, hitting $34.49. 677,198 shares of the stock were exchanged, compared to its average volume of 2,984,384. TG Therapeutics, Inc. has a 12 month low of $15.16 and a 12 month high of $46.48. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The firm has a market capitalization of $5.47 billion, a P/E ratio of -345.28 and a beta of 2.21. The company has a 50-day simple moving average of $38.38 and a two-hundred day simple moving average of $34.09.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing analysts' consensus estimates of $0.19 by ($0.16). The business had revenue of $120.86 million for the quarter, compared to the consensus estimate of $117.07 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. TG Therapeutics's revenue was up 90.4% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.07) earnings per share. On average, analysts forecast that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. HC Wainwright reaffirmed a "buy" rating and set a $55.00 price target on shares of TG Therapeutics in a report on Tuesday, March 4th. Wall Street Zen raised shares of TG Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $40.80.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.